Extracellular vesicles: the key for precision medicine in glioblastoma


Posted: 2021-09-28 19:00:00
Neuro Oncol . 2021 Sep 28;noab229. doi: 10.1093/neuonc/noab229. Online ahead of print. Affiliations Expand Affiliations 1 Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy. 2 Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. 3 IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy. 4 Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. 5 Department of Neurological Surgery, Johns Hopkins Medical School, Baltimore, USA. 6 Department of Translational Medicine, Piemonte Orientale University "Amedeo Avogadro," Novara, Italy. Item in Clipboard Massimiliano Del Bene et al. Neuro Oncol. 2021. Show details Display options Display options Format Neuro Oncol . 2021 Sep 28;noab229. doi: 10.1093/neuonc/noab229. Online ahead of print. Affiliations 1 Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy. 2 Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. 3 IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy. 4 Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. 5 Department of Neurological Surgery, Johns Hopkins Medical School, Baltimore, USA. 6 Department of Translational Medicine, Piemonte Orientale University "Amedeo Avogadro," Novara, Italy. Item in Clipboard CiteDisplay options Display options Format Abstract Glioblastoma (GBM) represents the most aggressive and lethal disease of the central nervous system. Diagnosis is delayed following the occurrence of symptoms, and treatment is based on standardized approaches that are unable to cope with its heterogeneity, mutability, and invasiveness. The follow-up of patients relies on burdensome schedules for magnetic resonance imaging (MRI). However, to personalize treatment, biomarkers and liquid biopsy still represent unmet clinical needs. Extracellular vesicles (EVs) may be the key to revolutionize the entire process of care for patients with GBM. EVs can be collected noninvasively (e.g., blood) and impressively possess multilayered information, which is constituted by their concentration and molecular cargo. EV-based liquid biopsy may facilitate GBM diagnosis and enable the implementation of personalized treatment, resulting in customized care for each patient and for each analyzed time point of the disease, thereby tackling the distinctive heterogeneity and mutability of GBM that confounds effective treatment. Herein, we discuss the limitations of current GBM treatment options and the rationale behind the need for personalized care. We also review the evidence supporting GBM-associated EVs as a promising tool capable of fulfilling the still unmet clinical need for effective and timely personalized care of patients with GBM. Keywords: biomarker; extracellular vesicles; glioblastoma; liquid biopsy. © The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. [x] Cite Copy Format: Send To [x]

参考サイト PubMed: exsome



バイオクイックニュース日本語版:エクソソーム特集

バイオクイックニュース日本語版
2月 19, 2021 バイオアソシエイツ

オンチップ生合成したNK細胞由来エクソソームが、非小細胞肺癌に対して抗腫瘍活性を示す

ミシガン大学ローゲル癌センターとミシガン大学工学部の研究者らは、癌と戦うためのナチュラルキラー免疫細胞の配備という新たな治療法の開発の面で一歩進んでいる。この研究者らは、ナチュラルキラー細胞をキャプチャーし、それらに癌を殺す エクソソーム を放出させる最初の体系的な方法を開発した。…

ゲスト 510人 と メンバー 2人 がオンラインです